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Introduction: Immune thrombocytopenia (ITP) is an immune disorder commonly presents as isolated
thrombocytopenia. Generally corticosteroids are the main treatment of ITP. This study was designed to evaluate
effectiveness of high dose dexamethasone comparing conventional corticosteroid therapy in the treatment of ITP.
Materials and methods: In a randomized prospective study, sixty adult patients with newly diagnosed primary
symptomatic ITP (Platelet count < 20,000) were evaluated. Patients divided into two groups. In group A, thirty
patients (mean age of 24.9 years) received Dexamethasone 40 mg/IV/daily for four days (10 mg/q6h); and then
Prednisolone 1 mg/kg/day/PO with rapid tapering of prednisolone (10 mg/week). From the other hand, in group B,
thirty patients (mean age of 27.2 years) were treated with Prednisolone 1 mg/kg/day/PO for four weeks, then the
drug tapered weekly.
Results: All the patients in group A showed favorable response within the first seven days, 27 cases presented
complete response (CR) and three cases revealed response (R). In group B, 11 cases had CR, 13 cases showed R and
six cases had No response (NR). After three months, rates of CR were 80% and 23.3% in group A and B; respectively.
Responses were 16.7% and 33.3%, NRs were 6.6% and 43.3% in group A and B; respectively (P < 0.0001). After
6 months, CR was 73.3% vs.16.7%, and R was 16.7% vs.36.7% and NR was 10% vs. 46.7% in group A and B;
respectively (P < 0.0001). After 12 months, there was no change in response rate in group A, but in group B 53%
were non responsive, 40% showed R (chronic ITP) and complete response was observed only in 6.7% (P < 0.0001).
Three cases in group A and 12 cases in group B had needed splenectomy (P < 0.00002).
Conclusion: We showed that high dose dexamethasone is more effective than conventional steroid therapy in
newly diagnosed ITP as initial treatment with less relapses and toxicities.
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The primary immune thrombocytopenia (ITP) is an iso-
lated thrombocytopenia without exogenous etiologic fac-
tors and secondary causes (1,2). Pathogenesis of ITP is
due to platelet specific autoantibodies (most commonly
IgG type) that bind to the platelet surface and cause* Correspondence: dralimashhadi@yahoo.com
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reproduction in any medium, provided the orclearance of them in spleen and liver (3,4). Treatment in
patients with ITP is dynamic and may alter in various
situations. Patients with life threatening bleeding may
need treatment with glucocorticoids, IVIG, platelet
transfusion, plasmapheresis or even emergency splenec-
tomy as initial treatment (5,6). Initial response to con-
ventional prednisolone therapy (1-2 mg/kg/day) varies
from 65% to 85%, but sustained response has been
reported to be less than 25% (7). Terminology used in
this manuscript was according to an international work-
ing group in 2009 (8). Use of high dose dexamethasoneral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 2 General characteristics of patients
Group A Group B P value
Sex(F/M) 24/6 23/7 0.75
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number of studies have reported good response rate
with minimal toxicity (9-11). The aim of this perspective
randomized trial was to evaluate effectiveness of single
course of high dose dexamethasone comparing conven-
tional prednisolone therapy in the treatment of newly














CR 27 (90) 11 (36.7)
R 3 (10) 13 (43.3)
NR 0 (0) 6 (20)
Three months < 0.0001
CR 24 (80) 7 (23.3)
R 5 (16.7) 10 (33.3)
NR 2 (6.6) 13 (43.3)Methods
In a single-blind randomized prospective study in Ali-
Ebne-Abitaleb hospital in Zahedan, newly diagnosed
adult patients with ITP were evaluated. Our inclusion
criteria were: newly diagnosed primary ITP with platelet
count less than 20,000/microliter. Bleeding tendency was
graded as a previously definition (Table 1) (12). The
study protocol was approved by regional medical ethical
committee (Approved No; 328, 2007.2.24) and all of
the patients provided informed consent. Patients with
previously treated ITP, diabetes, liver and kidney dys-
function, infections including HIV, HCV, and HBV, preg-
nancy and SLE or any acute illness were excluded. ITP
was diagnosed according to clinical features, CBC, and
bone marrow aspiration (13,14). After initial clinical
evaluation and performing CBC, bone marrow aspir-
ation was done. Collagen vascular diseases or anti
phospholipid antibody and other hematologic disorders
were ruled out using appropriate tests. Patients ran-
domly divided into two groups: group A received dexa-
methasone 40 mg/day/IV (10 mg/q6h) for four days and
then prednisolone 1mg/kg/day/PO with 10 mg/week
tapering and discontinuation after 6 weeks. Group B
treated with prednisolone 1mg/kg/day for four weeks and
then tapering 10 mg/week. Peripheral blood smear and
CBC checked daily during hospitalization, then weekly
for 6 weeks, and then monthly. Response to treatment
was classified to complete response (CR) (PLT count
>100,000), response (R) (PLT count ≥30,000) and no re-
sponse (NR) (no rising in PLT or PLT count < 30,000 or
symptomatic bleeding) [8]. Patients were followed for at
least 12 months (ranged 12-48 months) (Table 2, 3).
Toxicities were graded according to CTCAE criteria
(12,15).Table 1 Grade and type of bleeding symptom
Grade Type of bleeding
0 Absent
1 Petechiae
2 Ecchymoses and/or dripping with moderate loss of blood
3 Major mucous hemorrhage with copious loss of
blood without sequelae
4 Major mucous and/or parenchymal hemorrhage with
copious loss of blood with sequelae and/or life-threateningStatistical analysis: Data analysis was performed using
SPSS version 16 (SPSS Inc, Chicago, IL, USA). Inde-
pendent T test was used for comparison of continuous
variables. Differences in the distribution of variables be-
tween groups were analyzed by the X2 or Fisher exact
test. P < 0.05 was regarded as significant.Results
Sixty patients completed the study and came for weekly
follow up visits and laboratory evaluations. These con-
secutive patients randomly assigned to group A and B.
There was no significant difference between mean age
(P = 0.49), sex (P = 0.75) and platelet count (P = 0.56) of
the two groups (Table 2).Six months < 0.0001
CR 22 (73.3) 5 (16.6)
R 5 (16.6) 11 (36.7.3)
NR 3 (10) 14 (46.7)
One year < 0.0001
CR 22 (73.3) 2 (6.6)
R 5 (16.6) 12 (40)
NR 3 (10) 16 (53.3)
Splenectomy 3 (10) 12 (40) < 0.0002
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group A, CR and R were observed in 27 and three
patients, respectively. In group B, we showed CR in 11
cases, R in 13 cases and NR in six cases. After three
months, in group A, two patients were NR, five cases
showed R and 23 cases revealed CR and loss of CR and
R occurred in this period. In group B, NR, R and CR
were observed in 13, 10 and seven patients, respectively
(P < 0.0001). After 6 months, in group A versus group B,
the number of patients with NR, R and CR were three
versus 14, five versus 11 and 22 versus five (P < 0.0001).
One year after the initial treatment, there were no fur-
ther changes in group A; however, in group B, number
of NR cases increased to 16, two cases showed CR and
the remaining cases were in R group (P < 0.0001). Splen-
ectomy as a second line treatment was performed for
three cases in A group and for 12 cases in group B
(P < 0.00002) (Table 3).
Overall, treatment related toxicities (Table 4) were
minimal. Adverse reactions in group B were more com-
mon than group A. In group A, treatment related toxici-
ties were weight gain in five cases (17.3%) (All grade 1),
abnormal glucose level (grade 2 toxicity) needed transi-
ent treatment in one case, gastrointestinal distress in
two cases (one case in grade 2 and another in grade
three toxicity) and grade one hypertension in one case.
In group B, the most common toxicities were weight
gain in 13 cases (43.3%) with grade one toxicity, hyper-
tension in three cases (10%), (one case in grade 2 and
two cases in grade 1 toxicity), abnormal glucose level
needed transient treatment in five cases (16.5%) (three
in grade 2 and two in grade one of toxicity), and gastro-
intestinal toxicity in seven (23.3%) patients, (five in grade
2 and two in grade 3 of toxicity).Table 4 Treatment related toxicity
Group A No. (%) Group B No. (%)
Weight gain 5(17.3) 13(43.3)
Grade of toxicity : 1 Grade of toxicity : 1
Glucose intolerance 1(3.3) 5(16.5)
Grade of toxicity : 2 Grade of toxicity :
3 cases grade : 2
2 cases grade : 1
Hypertension 1(3.3) 3(10)
Grade of toxicity : 1 Grade of toxicity :
One case grade : 2
2 cases grade 1
Gastrointestinal distress 2(6.6) 7(23.3)
Grade of toxicity : 1 Grade of toxicity : 1
1 case grade 2 5 cases: grade 2
1 case grade 3 2 cases : grade 3Discussion
The standard treatment of ITP is corticosteroid therapy,
mainly prednisolone at 1mg/kg for four weeks and then
tapering (16). Although response rate to this therapeutic
regimen has been reported 50-60%, durability is low
(10-25%) (7,17).Our results showed that single course of
high dose dexamethasone regimen is more effective than
conventional therapy as an initial treatment for ITP
patients.
Cheng and colleagues demonstrated that 85% of all
cases received high dose dexamethasone had initial re-
sponse, while half of them had sustained response. Other
cases experienced relapse disease (PLT< 30,000). How-
ever, 50% of these cases only needed 10 mg/day prednis-
olone to continue response after second course of high
dose dexamethasone and other cases needed more than
10 mg/day plus further treatment including splenec-
tomy, IVIG, Anti D, danazol, vina alkaloid, and Cyclo-
sporine. In our study initial response was similar to
Cheng study, but we showed higher sustained and dur-
able response and lower relapse rate (16.6% vs. 50%).
This difference may be due to younger age of our
patients and continuation of prednisolone for at least
four weeks. The later probable reason may be supported
by this fact that in cheng study 50% of relapses
responded to 10 mg prednisolone (9).
In another study Borst and coworkers treated 36 cases
with high dose dexamethasone; 50% as first line therapy
and 50% as second line. In first line group 59% had dur-
able response (CR +PR) for 2-31 months, 28% had tran-
sient response with immediate relapse after cessation of
high dose dexamethasone and 11% had no response
(18). In second line group 25% had durable response
(CR+PR) for 4 – 54 months, 61% had transient re-
sponse and 11% had no response. In both groups 30.5%
of patients underwent splenectomy. In this study 44%
had no evidence of any side effect, 13.8% had severe tox-
icity and refused this modality of treatment.
In 2007 Mazzucconi and colleagues conducted two
studies: In a mono-center study 37 adult patients trea-
ted with 4-6 cycles of high dose dexamethasone every
28 days. Response rate was 89.2% (CR :62.2%, PR:
21.6%, MR: 5.4%, and NR in 10.8%). In this study, re-
lapse rate and durable response were 24.2% and 75%,
respectively. Sustained response was similar to our
study (67.6% vs. 75%). Thirty three cases showed a fa-
vorable response to dexamethasone therapy and relapse
occurred in eight cases which were higher than our
ones. In the Multicenter study response rate was 85.6%
(CR 64.5%; PR 20%; MR 1.1% and NR14.4%). With ad-
ministration of every other course of high dose dexa-
methasone therapy, response rate increased (69.5%,
75.5%, 89%). The quality of response in younger patients
was more favorable than older patients (P=0.039) and
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ant factor for response and relapse in Mazzucconi study.
After 6.5 months of treatment, relapse rate was 13% among
responders. Durable response without any treatment after
8 months follow up was 74.4% (13).
Compared to multicenter results, our patients were
adults and duration of follow up was longer (12-48 vs.
3-24 months). Durable response was similar in both stud-
ies; however CR was lower in multicenter study (64.5% vs.
80%) and relapse rate was higher (22% vs. 16.6%).
The younger mean age of our patients and continu-
ation of glucocorticoid after cessation of dexamethasone,
may explain more favorable response especially higher
durable response in our study.
The favorable and better outcome of current study
comparing Mazzucconi and Cheng studies were: young
age of our patients and continuation of corticosteroid
administration after cessation of high dose dexameha-
sone. Continuation of prednisolone may be effective in
sustained blockade of clearance system and inhibition of
antibody synthesis and deposition (19-22).
The strengths of our study were: the first randomized
prospective study about comparison between high dose
dexamethasone and conventional prednisolone therapy,
being all cases in severe disease according to PLT count
and doing close follow up visits. Our limitations were:
Age distribution (excluding childhood and older cases),
and single-blind study (instead of double-blind), and lim-
ited number of patients (only 30 cases in every groups).
Conclusion
Comparing conventional treatment, our study showed
more effectiveness of single course of high dose dexa-
methasone with continuation and rapid tapering of pred-
nisolone as an initial treatment for primary newly
diagnosed immune thrombocytopenia with minimal and
acceptable side effects. We recommend further head to
head studies to evaluate effectiveness of this regimen
comparing repeated cycles of dexamethasone as sole
treatment.
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